A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis

Key facts

Sponsor

Amgen

Principal Investigator

MD

Amgen

Intervention

Apremilast(drug)

Enrollment

48 enrolled

Eligibility

5-18 years · All sexes

Timeline

2023 – 2036

Study locations (7)

• General Hospital of Thessaloniki Ippokrateio, Thessaloniki, Greece
• Meir Medical Center, Kfar Saba, Israel
• Hospital Universitari i Politecnic La Fe, Valencia, Valencia, Spain
• Hospital Universitario Ramon y Cajal, Madrid, Spain
• Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey (Türkiye)
• Istanbul Universitesi Cerrahpasa Tip Fakultesi, Istanbul, Turkey (Türkiye)
• Umraniye Egitim ve Arastirma Hastanesi, Istanbul, Turkey (Türkiye)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Psoriasis-related juvenile idiopathic arthritis

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE1NCT06751238
  Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).
  Novartis Pharmaceuticals
• RECRUITINGPHASE3NCT06869551
  A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis
  Bristol-Myers Squibb
• RECRUITINGPHASE3NCT06668181
  An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
  UCB Biopharma SRL
• RECRUITINGPHASE3NCT06100744
  A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab
  AbbVie
• ACTIVE NOT RECRUITINGPHASE3NCT05083182
  A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
  Janssen Research & Development, LLC
• RECRUITINGPHASE3NCT04804553
  Apremilast Pediatric Study in Children With Active Juvenile Psoriatic Arthritis
  Amgen
• ACTIVE NOT RECRUITINGPHASE3NCT04527380
  A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
  Eli Lilly and Company

See all trials for Psoriasis-related juvenile idiopathic arthritis →